Mail-Order Pharmacies Deliver Peace of Mind During COVID

OSRX ships post-op drops directly to your practice or patients at no added cost, allowing at-risk patients to avoid unnecessary visits to the pharmacy before and after surgery.

Improving Patient Compliance With Compounded Glaucoma Medications

Glaucoma Physician spoke with Steven R. Sarkisian Jr., MD, about how using compounded medications can benefit both patients and providers.

OSRX Launches Online Prescriber Portal

OSRX, the 503A compounding pharmacy affiliate of Southern California biotech Ocular Science®, today introduced an online portal designed to streamline and simplify the prescribing process. The OSRX Prescriber Portal, at osrxpharmaceuticals.com, is a simplified, secure process for submitting, tracking and managing patient scripts.

Drug options proliferate for cataract surgery patients

Dr. Goldberg previously preferred brand-name drug products, but as prices increased sharply over the last 10 years, his practice started to look for alternative solutions, such as compounding. He has become a regular user of a compounded combination of topical antibiotic, steroid, and NSAID (prednisolone/gatifloxacin/bromfenac, OMNI by OSRX).

Compounded drops save time, money

by Gary Wörtz, MD — In my opinion, compounded drops are the closest thing we have seen to the holy grail of postop pharmaceuticals in my career. Not only do compounded drops save patients money, the quality and convenience compared with both brand-name and generic formulations have piqued the interest of both providers and patients.

Why I Prescribe OMNI Combo Drops

Dr. Steven R. Sarkisian, Jr., is the founder and CEO of Oklahoma Eye Surgeons, PLLC, as well as the former director of the glaucoma fellowship at the Dean McGee Eye Institute and clinical professor of Ophthalmology at the University of Oklahoma.

As Profits Rise, Ocular Science Promotes From Within

Ocular Science, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has promoted Eric Garner to Vice President of Marketing.

Ocular Science Taps Ophthalmology Medical Device Pro to Lead U.S. Sales

Ocular Science®, which produces and markets ophthalmic formulations for post-op cataract and LASIK procedures, glaucoma management, myopia control and dry eye disease, has named Greg Anderson as its vice president of sales.

Simplify Drop Use

It is agreed that controlling inflammation and managing infection risk, via steroids and NSAIDS and antibiotics, respectively, are of monumental importance following cataract surgery.

Ocular Science Launches Two Affiliates to Focus on Compounding and Biologic Sectors

Ocular Science launches two affiliates to focus on compounding and biologic sectors of ophthalmic market.

ASCRS FDA Committee Member Speaks on Access to Compounded Drugs

ASCRS FDA committee member Damien Goldberg, MD, urges FDA to allow access to compounded drugs from traditional compounders without a patient-specific prescription.